Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.70 |
| ▸ | RELA | Q04206 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 9/20 | 0.58 |
| ▸ | HTR2A | P28223 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869045 | 0.91 | TP53 (0.58) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL3462953 | 0.89 | NPC1 (0.70) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL14826631 | 0.84 | HTR2C (0.74) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL10197543 | 0.84 | NPC1 (0.70) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL382910 | 0.83 | NPC1 (1.00) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6636520 | 0.81 | HTR2C (0.47) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL4863733 | 0.81 | TP53 (0.58) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL583556 | 0.80 | ADRB2 (0.55) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL4870827 | 0.80 | PDK1 (0.56) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL3036883 | 0.80 | HTR2C (0.76) | NPC1RAB9ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2185572-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | G6PC1, PYGL, PPP1CA | NPC1 4463/4885RAB9A 2539/4885NFKB1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.